SEARCH:   Advanced

Blood, 1 September 2004, Vol. 104, No. 5, pp. 1253-1257. Prepublished online as a Blood First Edition Paper on March 9, 2004; DOI 10.1182/blood-2003-11-3854. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-11-3854v1 104/5/1253    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wenstrup, R. J. Articles by Sun, S. Search for Related Content PubMed PubMed Citation Articles by Wenstrup, R. J. Articles by Sun, S. Related Collections Phagocytes Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy Richard J. Wenstrup, Laurie Bailey, Gregory A. Grabowski, Jay Moskovitz, Alan E. Oestreich, Wei Wu, and Shumei Sun From the Division of Human Genetics and the Department of Radiology, Children's Hospital Research Foundation, Cincinnati, OH; and the Department of Community Health, Wright State University, Dayton, OH. Symptomatic patients with Gaucher disease (GD) (acid -glucosidase [Gcase] deficiency) are treated with injectable human recombinant GCase. Treatment results in significant decreases in lipid storage in liver, spleen, and bone marrow, but the generalized osteopenia and focal bone lesions present in many adult patients are refractory to treatment. A double-blind, 2-arm, placebo-controlled trial of alendronate (40 mg/d) was performed in adults with GD who had been treated with enzyme for at least 24 months. Primary therapeutic endpoints were improvements in (1) bone mineral density (BMD) and content (BMC) at the lumbar spine, and (2) focal lesions in x-rays of long bones assessed by a blinded reviewer. There were 34 patients with GD type 1 (age range, 18-50 years) receiving enzyme therapy who were randomized for this study. After 18 months, BMD at the lumbar spine was 0.068 ± 0.21 and 0.015 ± 0.034 for alendronate and placebo groups, respectively (P = .001). Long-bone x-rays showed no change in focal lesions or bone deformities in any subject in either arm. Alendronate is a useful adjunctive therapy in combination with enzyme replacement therapy (ERT) for the treatment of GD-related osteopenia in adults, but it cannot be expected to improve focal lesions. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Bembi, E. Cerini, C. Danesino, M. A. Donati, S. Gasperini, L. Morandi, O. Musumeci, G. Parenti, S. Ravaglia, F. Seidita, et al. Management and treatment of glycogenosis type II Neurology, December 2, 2008; 71(23_suppl_2): S12 - S36. [Abstract] [Full Text] [PDF] C. J. Dean, M. R. Bockmann, J. J. Hopwood, D. A. Brooks, and P. J. Meikle Detection of Mucopolysaccharidosis Type II by Measurement of Iduronate-2-Sulfatase in Dried Blood Spots and Plasma Samples Clin. Chem., April 1, 2006; 52(4): 643 - 649. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020